| Literature DB >> 24919413 |
Kang Huang1, Chang-Wen Xu, Bo Zeng, Qing-Qing Xia, An-Yun Zhang, Chang-Wei Lei, Zhong-Bin Guan, Han Cheng, Hong-Ning Wang.
Abstract
Escherichia coli resistance to quinolones has now become a serious issue in large-scale pig farms of China. It is necessary to study the dynamics of quinolone resistance in fecal Escherichia coli of pigs after antimicrobial administration. Here, we present the hypothesis that the emergence of resistance in pigs requires drug accumulation for 7 days or more. To test this hypothesis, 26 pigs (90 days old, about 30 kg) not fed any antimicrobial after weaning were selected and divided into 2 equal groups: the experimental (EP) group and control (CP) group. Pigs in the EP group were orally treated daily with 5 mg ciprofloxacin/kg of body weight for 30 days, and pigs in the CP group were fed a normal diet. Fresh feces were collected at 16 time points from day 0 to day 61. At each time point, ten E. coli clones were tested for susceptibility to quinolones and mutations of gyrA and parC. The results showed that the minimal inhibitory concentration (MIC) for ciprofloxacin increased 16-fold compared with the initial MIC (0.5 µg/ml) after ciprofloxacin administration for 3 days and decreased 256-fold compared with the initial MIC (0.5 µg/ml) after ciprofloxacin withdrawal for 26 days. GyrA (S83L, D87N/ D87Y) and parC (S80I) substitutions were observed in all quinolone-resistant E. coli (QREC) clones with an MIC ≥8 µg/ml. This study provides scientific theoretical guidance for the rational use of antimicrobials and the control of bacterial resistance.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24919413 PMCID: PMC4197147 DOI: 10.1292/jvms.14-0025
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Primers used in this study
| Target gene | Primers | Sequence (5′-3′) | Size (bp) | Annealing temperature (°C) | Accession no. |
|---|---|---|---|---|---|
| CGACCTGAGCGGCACTGAAT | 515 | 57.5 | DQ351241 | ||
| TGAGCAACGATGCCTGGTAG | |||||
| CATACATATCGGCACCACAAC | 637 | 56 | EF683584 | ||
| CAGGATAAACAACAATACCCAGT | |||||
| aac (6’) Ib-cr | aac -F | TTGCGATGCTCTATGAGTGGCTA | 482 | 55 | EF465463 |
| aac -R | CTCGAATGCCTGGCGTGTTT | ||||
| GATCAGTCAGTGGGATAGTTT | 627 | 55 | HQ674771 | ||
| TACTCGGCGTTAACTGATTA |
Fig. 1.The number of QREC and total E. coli strains in fecal samples collected from experimentally treated pigs at 16 time points.
Fig. 2.The average MIC of E. coli clones (n=10) from fecal samples at 16 time points in the experimental group of pigs and at 8 time points in the control group of pigs. Bars indicate the standard deviation between MICs.
Characteristics of E. coli isolates isolated from the fecal samples of pigs fed ciprofloxacin from days 1 to 30
| CIP use | Day of feces | Max MIC
( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CIP | NAL | NOR | LVX | mut 83 (n) | mut 87 (n) | mut 80 (n) | ||||
| Before ciprofloxacin administration | 0 | 1 | 64 | 1 | 1 | S83L (4) | ... | ... | ||
| After CIP administration | 1 | 16 | 512 | 16 | 16 | S83L (6) | D87N (4) | S80I (4) | ||
| 2 | 16 | 512 | 16 | 16 | S83L (6) | D87N (4) | S80I (6) | |||
| 4 | 16 | 512 | 16 | 32 | S83L (10) | D87N (10) | S80I (10) | |||
| 6 | 32 | >1024 | 32 | 32 | S83L (10) | D87N (10) | S80I (10) | |||
| 11 | 32 | >1024 | 32 | 32 | S83L (10) | D87N (4) | S80I (6) | |||
| 16 | 128 | >1024 | 32 | 32 | S83L (10) | D87N (4) D87Y (6) | S80I (10) | |||
| 21 | 128 | >1024 | 32 | 32 | S83L (10) | D87N (10) | S80I (10) | |||
| 26 | 128 | >1024 | 32 | 32 | S83L (10) | D87N (10) | S80I (10) | |||
| After CIP withdrawal | 31 | 128 | >1024 | 32 | 32 | S83L (10) | D87N (10) | S80I (10) | ||
| 36 | 32 | >1024 | 32 | 32 | S83L (10) | D87N (2) D87Y (8) | S80I (10) | |||
| 41 | 64 | >1024 | 16 | 16 | S83L (10) | D87N (10) | S80I (10) | |||
| 46 | 32 | 512 | 16 | 32 | S83L (10) | D87N (10) | S80I (10) | |||
| 51 | 8 | 512 | 16 | 16 | S83L (10) | D87N (4) | S80I (4) | |||
| 56 | 0.5 | 64 | 2 | 2 | S83L (10) | ... | ... | |||
| 61 | 1 | 64 | 2 | 2 | S83L (10) | ... | ... | |||
CIP: Ciprofloxacin, NAL: Nalidixic acid, NOR: Norfloxacin, LVX: Levofloxacin, MIC: Minimal inhibitory concentration, n: number of E. coli with a point mutation.
Fig. 3.Growth profiles of E. coli clones (n=5) from before ciprofloxacin administration (BS-E. coli, QSEC), after ciprofloxacin administration (R-E. coli, QREC) and after ciprofloxacin administration (AS-E. coli, QSEC).